Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Holdings Reduced by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC lowered its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 1.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,068 shares of the medical device company’s stock after selling 1,188 shares during the quarter. Mizuho Markets Americas LLC owned about 0.11% of Tandem Diabetes Care worth $3,014,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in TNDM. Assetmark Inc. bought a new stake in Tandem Diabetes Care during the 3rd quarter valued at $29,000. ORG Wealth Partners LLC acquired a new stake in Tandem Diabetes Care in the third quarter worth about $30,000. ORG Partners LLC acquired a new stake in Tandem Diabetes Care in the second quarter worth about $31,000. Headlands Technologies LLC bought a new position in Tandem Diabetes Care in the 1st quarter valued at about $35,000. Finally, Waldron Private Wealth LLC bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth about $50,000.

Analyst Ratings Changes

Several research firms have recently issued reports on TNDM. The Goldman Sachs Group initiated coverage on shares of Tandem Diabetes Care in a report on Friday, October 4th. They issued a “neutral” rating and a $46.00 price objective for the company. Wells Fargo & Company lifted their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Robert W. Baird cut their price objective on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a report on Thursday, November 7th. Morgan Stanley reaffirmed an “equal weight” rating and set a $45.00 target price on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Finally, UBS Group raised shares of Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of “Moderate Buy” and an average target price of $54.25.

Tandem Diabetes Care Stock Down 4.4 %

Shares of NASDAQ TNDM opened at $27.34 on Friday. Tandem Diabetes Care, Inc. has a one year low of $17.33 and a one year high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The business has a 50-day moving average price of $37.46 and a two-hundred day moving average price of $41.64.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The firm’s revenue was up 31.4% on a year-over-year basis. As a group, equities analysts expect that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.